Contineum Therapeutics, Inc. (CTNM) Balance Sheet
As of 2026-06-30 (10-Q), Contineum Therapeutics, Inc. (CTNM) reported total assets of $250.4M, total liabilities of $10.7M and shareholders' equity of $239.7M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $14.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTNMContineum Therapeutics, Inc.Follow CTNM — free
—
Price chart with a free account
- Market cap
- 312.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 17 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 21.9 | 75.6 | 14.7 | |
| Short-term investments | 182.8 | 187.3 | 221.8 | |
| Current assets | 206.4 | 267.9 | 242.6 | |
| Total assets | 212.8 | 276.6 | 250.4 | |
| Current liabilities | 10.0 | 9.7 | 6.5 | |
| Total liabilities | 14.8 | 15.7 | 10.7 | |
| Shareholders' equity | 198.1 | 261.0 | 239.7 |
USD millions · SEC XBRL
Contineum Therapeutics, Inc. — questions
- How much cash does Contineum Therapeutics, Inc. have?
- $14.7M in cash and cash equivalents as of 2026-06-30.
- What are Contineum Therapeutics, Inc.'s total assets?
- $250.4M as of 2026-06-30.
- What is Contineum Therapeutics, Inc.'s shareholders' equity?
- $239.7M as of 2026-06-30.
Every figure on this page comes from Contineum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.